From Underperformance to Opportunity: Biotech's Case for 2025

Published on January 31, 2025

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking innovations like mRNA cancer vaccines and CRISPR-based therapies.

Continue reading on website
Other news

Weekly Economic Snapshot: Signs of Strength & Softness

January 31, 2025
Economic indicators provide insight into the overall health and performance of the economy. They are closely watched by many.

Q4 Tech Earnings: Will CapEx Take Bite of Profits?

January 31, 2025
Guidance and spending will be important to watch as analysts have their eyes on annual revenue growth, especially after news of DeepSeek shocked U.S. markets.